Nevertheless, patients in the “no hypometabolism” subtype showed a comparably high proportion of concomitant tau biomarker positivity as the other subtypes in the prodromal AD group (86–90%; Supplementary Table 1). The gene discussed is MAPT; the disease is Alzheimer disease.